We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Henry Schein to Acquire SAS to Strengthen Dental Offerings
Read MoreHide Full Article
Just a day before its fourth-quarter earnings announcement, Henry Schein Inc. (HSIC - Free Report) announced its decision to acquire Southern Anesthesia + Surgical (SAS). SAS is a U.S.-based distributor in the field of anesthesia and surgical supplies, catering to oral surgeons, dental anesthesiologists and periodontists. Financial terms of the deal have not been disclosed.
This worldwide distributor of full-service dental products and services believes the acquisition of SAS to be a strategic one, uniting two leading dental-surgical supply companies. Henry Schein’s dental business will be enriched with SAS’ controlled and non-controlled pharmaceuticals, as well as surgical supplies which currently caters to approximately 11,500 customers and had sales of $72 million in 2016. SAS’ customers are expected to benefit from the broader array of products and services of Henry Schein.
SAS currently has an extensive product offering with over 13,000 stock keeping units and it serves all 50 states. Henry Schein plans to incorporate SAS’ business within its subsidiary ACE Surgical Supply Co. The company expects to close the acquisition in the second quarter of 2017 subject to regulatory approvals.
In this regard, we note that, Henry Schein has recently implemented inorganic means to harness growth in dental business. Last month, the company acquired a majority ownership interest in Dental Cremer – a distributor of dental supplies and equipment in Brazil.
Earlier in December, the company acquired Poland-based dental distributor Marrodent. The acquisition has paved the way for the company to expand its dental business among Poland’s approximately 26,000 practicing dentists and 20,000 dental offices. The company also completed its takeover of a 90% ownership stake in Dental Trey – an Italy-based distributor of dental consumable merchandise and equipment.
We believe the acquisition of SAS, post its closing, should also help in strengthening the company’s dental offerings and thereby boost its top line.
Share Price Movement
Over the past three months, Henry Schein has consistently traded above the Zacks categorized Medical - Dental Supplies industry. The stock is currently up 13.17% which is higher than 7.05% gain of the broader industry. Also Henry Schein recorded a CAGR of 5.7% over the last five years for revenues, reflecting strong fundamentals in its growth performance. Management earlier provided cautious 2017 guidance on North American dental business which has been plagued by several issues.
However, a rising share price trend is indicative of brighter days ahead. We expect the acquisition of SAS to be further helpful in holding investors’ optimism on the stock’s North America’s performance.
Zacks Rank & Key Picks
Henry Schein currently has a Zacks Rank #4 (Sell). Better-ranked medical stocks include Glaukos Corporation (GKOS - Free Report) , Cardiovascular Systems and Neogen Corp. (NEOG - Free Report) . Glaukos sports a Zacks Rank #1 (Strong Buy) while Cardiovascular Systems and Neogen carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Glaukos gained over 100% in the last one year compared with the S&P 500’s gain of 22.4%. The company has a stellar four-quarter average earnings surprise of over 100%.
Cardiovascular Systems surged over 100% in the last one year compared with the S&P 500. It has a four-quarter average earnings surprise of 67.8%.
Neogen gained 34.6% in the past one year, better than the S&P 500 mark. The stock has an impressive long-term earnings growth rate of 16.7% for the next five years compared with the industry average of 15.2%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Henry Schein to Acquire SAS to Strengthen Dental Offerings
Just a day before its fourth-quarter earnings announcement, Henry Schein Inc. (HSIC - Free Report) announced its decision to acquire Southern Anesthesia + Surgical (SAS). SAS is a U.S.-based distributor in the field of anesthesia and surgical supplies, catering to oral surgeons, dental anesthesiologists and periodontists. Financial terms of the deal have not been disclosed.
This worldwide distributor of full-service dental products and services believes the acquisition of SAS to be a strategic one, uniting two leading dental-surgical supply companies. Henry Schein’s dental business will be enriched with SAS’ controlled and non-controlled pharmaceuticals, as well as surgical supplies which currently caters to approximately 11,500 customers and had sales of $72 million in 2016. SAS’ customers are expected to benefit from the broader array of products and services of Henry Schein.
SAS currently has an extensive product offering with over 13,000 stock keeping units and it serves all 50 states. Henry Schein plans to incorporate SAS’ business within its subsidiary ACE Surgical Supply Co. The company expects to close the acquisition in the second quarter of 2017 subject to regulatory approvals.
In this regard, we note that, Henry Schein has recently implemented inorganic means to harness growth in dental business. Last month, the company acquired a majority ownership interest in Dental Cremer – a distributor of dental supplies and equipment in Brazil.
Earlier in December, the company acquired Poland-based dental distributor Marrodent. The acquisition has paved the way for the company to expand its dental business among Poland’s approximately 26,000 practicing dentists and 20,000 dental offices. The company also completed its takeover of a 90% ownership stake in Dental Trey – an Italy-based distributor of dental consumable merchandise and equipment.
We believe the acquisition of SAS, post its closing, should also help in strengthening the company’s dental offerings and thereby boost its top line.
Share Price Movement
Over the past three months, Henry Schein has consistently traded above the Zacks categorized Medical - Dental Supplies industry. The stock is currently up 13.17% which is higher than 7.05% gain of the broader industry. Also Henry Schein recorded a CAGR of 5.7% over the last five years for revenues, reflecting strong fundamentals in its growth performance. Management earlier provided cautious 2017 guidance on North American dental business which has been plagued by several issues.
However, a rising share price trend is indicative of brighter days ahead. We expect the acquisition of SAS to be further helpful in holding investors’ optimism on the stock’s North America’s performance.
Zacks Rank & Key Picks
Henry Schein currently has a Zacks Rank #4 (Sell). Better-ranked medical stocks include Glaukos Corporation (GKOS - Free Report) , Cardiovascular Systems and Neogen Corp. (NEOG - Free Report) . Glaukos sports a Zacks Rank #1 (Strong Buy) while Cardiovascular Systems and Neogen carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Glaukos gained over 100% in the last one year compared with the S&P 500’s gain of 22.4%. The company has a stellar four-quarter average earnings surprise of over 100%.
Cardiovascular Systems surged over 100% in the last one year compared with the S&P 500. It has a four-quarter average earnings surprise of 67.8%.
Neogen gained 34.6% in the past one year, better than the S&P 500 mark. The stock has an impressive long-term earnings growth rate of 16.7% for the next five years compared with the industry average of 15.2%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>